- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- SUN PHARMA - STERLING BIOTECH
SUN PHARMA vs STERLING BIOTECH - Comparison Results
SUN PHARMA 
Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
STERLING BIOTECH
Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
Current Valuations
| SUN PHARMA | STERLING BIOTECH | SUN PHARMA/ STERLING BIOTECH |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 44.7 | -0.5 | - | View Chart |
| P/BV | x | 3.6 | 0.0 | 18,756.8% | View Chart |
| Dividend Yield | % | 0.6 | 0.0 | - |
Financials
 SUN PHARMA  STERLING BIOTECH |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-17 |
STERLING BIOTECH Dec-13 |
SUN PHARMA/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 842 | 11 | 8,020.0% | |
| Low | Rs | 572 | 3 | 16,835.3% | |
| Sales per share (Unadj.) | Rs | 131.6 | 26.8 | 491.0% | |
| Earnings per share (Unadj.) | Rs | 32.7 | -15.0 | -218.6% | |
| Cash flow per share (Unadj.) | Rs | 38.0 | -5.5 | -695.1% | |
| Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
| Dividend yield (eoy) | % | 0.5 | 0 | - | |
| Book value per share (Unadj.) | Rs | 152.7 | 54.9 | 278.3% | |
| Shares outstanding (eoy) | m | 2,399.26 | 267.87 | 895.7% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 5.4 | 0.3 | 2,072.6% | |
| Avg P/E ratio | x | 21.6 | -0.5 | -4,654.2% | |
| P/CF ratio (eoy) | x | 18.6 | -1.3 | -1,463.9% | |
| Price / Book Value ratio | x | 4.6 | 0.1 | 3,657.2% | |
| Dividend payout | % | 10.7 | 0 | - | |
| Avg Mkt Cap | Rs m | 1,696,877 | 1,862 | 91,146.7% | |
| No. of employees | `000 | 17.5 | 1.4 | 1,293.6% | |
| Total wages/salary | Rs m | 49,023 | 547 | 8,965.4% | |
| Avg. sales/employee | Rs Th | 18,028.3 | 5,303.3 | 339.9% | |
| Avg. wages/employee | Rs Th | 2,798.8 | 403.8 | 693.0% | |
| Avg. net profit/employee | Rs Th | 4,479.5 | -2,959.0 | -151.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 315,784 | 7,181 | 4,397.7% | |
| Other income | Rs m | 6,232 | 43 | 14,627.9% | |
| Total revenues | Rs m | 322,016 | 7,223 | 4,458.0% | |
| Gross profit | Rs m | 100,893 | 947 | 10,655.1% | |
| Depreciation | Rs m | 12,648 | 2,543 | 497.3% | |
| Interest | Rs m | 3,998 | 4,377 | 91.3% | |
| Profit before tax | Rs m | 90,479 | -5,931 | -1,525.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 99 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 12,116 | -1,924 | -629.6% | |
| Profit after tax | Rs m | 78,462 | -4,007 | -1,958.4% | |
| Gross profit margin | % | 31.9 | 13.2 | 242.3% | |
| Effective tax rate | % | 13.4 | 32.4 | 41.3% | |
| Net profit margin | % | 24.8 | -55.8 | -44.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 329,537 | 14,335 | 2,298.8% | |
| Current liabilities | Rs m | 178,870 | 49,809 | 359.1% | |
| Net working cap to sales | % | 47.7 | -494.0 | -9.7% | |
| Current ratio | x | 1.8 | 0.3 | 640.1% | |
| Inventory Days | Days | 79 | 403 | 19.6% | |
| Debtors Days | Days | 83 | 171 | 48.8% | |
| Net fixed assets | Rs m | 204,766 | 55,432 | 369.4% | |
| Share capital | Rs m | 2,399 | 268 | 895.6% | |
| "Free" reserves | Rs m | 363,997 | 13,935 | 2,612.1% | |
| Net worth | Rs m | 366,397 | 14,701 | 2,492.3% | |
| Long term debt | Rs m | 14,361 | 9,478 | 151.5% | |
| Total assets | Rs m | 614,102 | 73,988 | 830.0% | |
| Interest coverage | x | 23.6 | -0.4 | -6,657.3% | |
| Debt to equity ratio | x | 0 | 0.6 | 6.1% | |
| Sales to assets ratio | x | 0.5 | 0.1 | 529.8% | |
| Return on assets | % | 13.4 | 0.5 | 2,680.8% | |
| Return on equity | % | 21.4 | -27.3 | -78.6% | |
| Return on capital | % | 24.8 | -6.4 | -386.5% | |
| Exports to sales | % | 0 | 25.9 | 0.0% | |
| Imports to sales | % | 0 | 0.2 | 0.0% | |
| Exports (fob) | Rs m | NA | 1,860 | 0.0% | |
| Imports (cif) | Rs m | NA | 12 | 0.0% | |
| Fx inflow | Rs m | 44,118 | 1,860 | 2,372.2% | |
| Fx outflow | Rs m | 24,484 | 25 | 98,369.2% | |
| Net fx | Rs m | 19,634 | 1,835 | 1,070.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 70,822 | 1,719 | 4,120.7% | |
| From Investments | Rs m | -42,216 | -3,148 | 1,341.0% | |
| From Financial Activity | Rs m | -22,854 | 1,426 | -1,602.7% | |
| Net Cashflow | Rs m | 6,107 | -3 | -179,608.8% | |
Share Holding
| Indian Promoters | % | 63.7 | 33.9 | 187.9% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 5.1 | 0.0 | - | |
| FIIs | % | 23.0 | 9.9 | 232.3% | |
| ADR/GDR | % | 0.0 | 16.9 | - | |
| Free float | % | 8.3 | 39.3 | 21.1% | |
| Shareholders | 133,026 | 21,482 | 619.2% | ||
| Pledged promoter(s) holding | % | 0.5 | 55.9 | 0.9% |
Compare SUN PHARMA With: DR. REDDYS LAB IPCA LABS JUBILANT LIFE SCIENCES VENUS REMEDIES PIRAMAL ENTERPRISES
Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends Lower; Tata Steel & Vedanta Top Losers(Closing)
Indian share markets erased early gains to end lower today, as the opposition parties tabled a no-confidence motion against Prime Minister Narendra Modi's government.
Related Views on News
SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%
May 28, 2018 | Updated on May 28, 2018For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)
Nov 20, 2017The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)
Jul 12, 2018Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.
The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)
Jul 10, 2018If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...
The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)
Jul 11, 2018The price signals that MSP sends out, creates its own set of problems.
New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)
Jul 6, 2018ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.
When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)
Jul 6, 2018Buy Companies that can fight all kinds of Pandas and Bears in the long run.
More|
| |
SUN PHARMA SHARE PRICE
Jul 18, 2018 (Close)
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 8-QTR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.